Table 2.

Unadjusted and adjusted models for outcomes according to residual inflammatory risk.

		Unadjusted Model		Adjusted Model
				Model 1		Model 2		Model 3
Event	Inflammatory Status	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
All-cause death	Persistent high	2.34 (1.64–3.39)	<0.001	2.18 (1.53–3.16)	<0.001	2.03 (1.39–3.00)	<0.001	2.08 (1.41–3.11)	<0.001
	Increased	2.97 (1.21–3.42)	0.009	2.07 (1.21–3.42)	0.009	1.97 (1.09–3.40)	0.026	2.05 (1.13–3.11)	0.019
	Attenuated	1.22 (0.76–1.91)	0.40	1.22 (0.77–1.92)	0.40	1.30 (0.80–2.07)	0.28	1.37 (0.84–2.18)	0.20
MACE	Persistent high	2.30 (1.49–3.63)	<0.001	2.17 (1.40–3.44)	<0.001	2.33 (1.45–3.82)	<0.001	2.38 (1.46–3.96)	<0.001
	Increased	2.13 (1.10–3.92)	0.026	1.96 (0.99–3.66)	0.054	2.24 (1.09–4.34)	0.029	2.35 (1.14–4.58)	0.022
	Attenuated	1.82 (1.11–3.01)	0.019	1.76 (1.06–2.92)	0.028	1.94 (1.14–3.30)	0.015	2.00 (1.17–3.43)	0.012

Patients with persistent low residual inflammatory risk (RIR) were used as references. Covariates of the fully adjusted model are as below. Model 1: age, sex, RIR. Model 2: age, sex, RIR, hypertension (HT), chronic kidney disease (CKD), diabetes mellitus (DM), dyslipidemia (DL), body mass index (BMI), smoking status, multivessel disease (MVD), left ventricular ejection fraction (LVEF). Model 3: age, sex, RIR, HT, CKD, DM, DL, BMI, smoking status, MVD, LVEF, low-density lipoprotein-cholesterol, high-density lipoprotein–cholesterol, triglycerides, use of statins. HR, hazard ratio; 95%CI, 95% confidence interval.